Weight Loss Drugs Cut Alcohol Hospitalizations by 32%

Weight loss drugs are delivering hope beyond the scale. A major study found that medications like Wegovy and Mounjaro lowered alcohol-related hospital admissions by up to 65% in people battling both obesity and alcohol problems.

Researchers tracked over 40,000 people taking these GLP-1 medications between 2018 and 2024. The drugs, which work by mimicking hormones that regulate blood sugar and appetite, appear to affect alcohol cravings too.

The results varied by group but remained promising across the board. For people using the drugs specifically for weight loss, alcohol-related hospitalizations dropped 32% compared to those on other obesity medications. Among diabetics taking the drugs, the reduction was 26% compared to other diabetes treatments.

The most dramatic results came from people dealing with both weight issues and alcohol problems. Type 2 diabetics with alcohol use disorder saw a 63% drop in alcohol-related hospitalizations. Obese individuals with alcohol problems experienced a 65% reduction.

These findings matter in a big way. England alone reported over one million alcohol-related hospital admissions in 2023 and 2024. If these medications can genuinely reduce that burden, they could transform treatment for addiction while addressing other health conditions.

The Bright Side

Scientists are cautiously optimistic but honest about the limitations. This US study observed real-world patterns rather than running a controlled trial. Researchers noted that people who can afford these expensive medications might differ from those who cannot in ways that affect the results.

Professor Colin Angus from Sheffield University praised the research while urging measured expectations. He pointed out that wealthier people with better insurance are more likely to access these treatments, which could influence the findings.

Still, this study adds weight to growing evidence that GLP-1 medications might help combat addiction. The drugs appear to affect reward pathways in the brain beyond just appetite, potentially curbing cravings for alcohol alongside food.

Researchers published their findings in BMJ Open and called for more investigation. They believe GLP-1 medications "may suggest a potential role" in treating alcohol use disorder, though rigorous clinical trials are needed to confirm the connection.

The discovery opens exciting possibilities for treating multiple conditions with one medication, offering hope to millions managing overlapping health challenges.